Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lemzoparlimab by AbbVie for Follicular Lymphoma: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...
Lemzoparlimab by AbbVie for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of I-Mab's Lemzoparlimab?
Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Solid Tumor. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of I-Mab's Lemzoparlimab?
Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...